Figure 4.

Both CD22 CART^pos and CART^neg exhibit in vivo anti-leukemic activity

(A) On day 0, luciferase⁺ NALM6 cells (1 × 10⁶) were injected via tail vein into NSG mice, followed by the injection of CD22 CART^pos and CART^neg (3 × 10⁶) at day 4. Leukemia growth was evaluated over 50 days by bioluminescent imaging and images at the indicated time points are presented. (B) Bioluminescence ±SEM at each time point was quantified and tumor progression in each mouse is shown.